AMITRIPTYLINE HYDROCHLORIDE Drug Patent Profile

Which patents cover Amitriptyline Hydrochloride, and what generic alternatives are available?

Amitriptyline Hydrochloride is a drug marketed by Watson Labs, Accord Hlthcare, Aiping Pharm Inc, Am Therap, Ani Pharms, Aurobindo Pharma Usa, Breckenridge, Copley Pharm, Halsey, Lederle, Mankind Pharma, Mutual Pharm, Par Pharm, Ph Health, Pliva, Purepac Pharm, Rising, Roxane, Rubicon Research, Sandoz, Sun Pharm Inds Inc, Superpharm, Teva, Ucb Inc, Unichem, Unique Pharm, Usl Pharma, Vangard, West Ward, and Zydus Pharms. and is included in one hundred and twenty NDAs.

The generic ingredient in AMITRIPTYLINE HYDROCHLORIDE is amitriptyline hydrochloride. There are thirteen drug master file entries for this compound. Thirty-three suppliers are listed for this compound. Additional details are available on the amitriptyline hydrochloride profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Amitriptyline Hydrochloride

A generic version of AMITRIPTYLINE HYDROCHLORIDE was approved as amitriptyline hydrochloride by SUN PHARM INDS INC on July 14^th, 1987.

Summary for AMITRIPTYLINE HYDROCHLORIDE

US Patents:	0
Applicants:	30
NDAs:	120
Finished Product Suppliers / Packagers:	33
Raw Ingredient (Bulk) Api Vendors:	1
Clinical Trials:	136
Patent Applications:	3,800
DailyMed Link:	AMITRIPTYLINE HYDROCHLORIDE at DailyMed

Recent Clinical Trials for AMITRIPTYLINE HYDROCHLORIDE

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Md. Moktadirul Hoque Shuvo	PHASE2
Zagazig University	NA
Ain Shams University	NA

See all AMITRIPTYLINE HYDROCHLORIDE clinical trials

Pharmacology for AMITRIPTYLINE HYDROCHLORIDE

Drug Class

Tricyclic Antidepressant

Medical Subject Heading (MeSH) Categories for AMITRIPTYLINE HYDROCHLORIDE

Adrenergic Uptake Inhibitors

Analgesics, Non-Narcotic

Antidepressive Agents, Tricyclic

Anatomical Therapeutic Chemical (ATC) Classes for AMITRIPTYLINE HYDROCHLORIDE

N06AA	Non-selective monoamine reuptake inhibitors
N06A	ANTIDEPRESSANTS
N06	PSYCHOANALEPTICS
N	Nervous system

US Patents and Regulatory Information for AMITRIPTYLINE HYDROCHLORIDE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Par Pharm	AMITRIPTYLINE HYDROCHLORIDE	amitriptyline hydrochloride	TABLET;ORAL	088700-001	Sep 25, 1984		DISCN	No	No
Rising	AMITRIPTYLINE HYDROCHLORIDE	amitriptyline hydrochloride	TABLET;ORAL	217411-005	May 19, 2023	AB	RX	No	No
Halsey	AMITRIPTYLINE HYDROCHLORIDE	amitriptyline hydrochloride	TABLET;ORAL	085922-001	Approved Prior to Jan 1, 1982		DISCN	No	No

Market Dynamics and Financial Trajectory for Amitriptytyline Hydrochloride

Last updated: February 20, 2026

What is the current market landscape for amitriptyline hydrochloride?

Amitriptyline hydrochloride remains a widely prescribed tricyclic antidepressant primarily used for depression, chronic pain, migraines, and off-label indications. Despite declines in antidepressant prescriptions generally, demand persists due to its efficacy in off-label applications and low-cost profile. The global market size was valued at approximately USD 1.1 billion in 2022 and is projected to grow at a compound annual growth rate (CAGR) of 2.1% through 2030.[1]

Key players and market share

• Teva Pharmaceutical Industries
• Mylan (now part of Viatris)
• Allergan (AbbVie)
• Sun Pharmaceutical
• Sun Pharma controls roughly 40% of the market, owing to its extensive manufacturing footprint and low-cost generics.
• Other companies account for the remaining share.

Distribution channels

The drug is sold through:

• Generics pharmacies
• Hospital pharmacies
• Online platforms

How do regulatory and patent factors influence the market?

Amitriptyline hydrochloride’s patent expired in 1989, transitioning the market to generic drugs. This exposure to biosimilar competition decreased the potential for patent-driven premium pricing. Regulatory approvals are straightforward for generic producers, with WHO prequalification and US FDA approval as key markers of market acceptability.

What are the key drivers impacting market growth?

• Chronic pain treatment: An increase in conditions like neuropathic pain sustains demand.
• Off-label use: Efficacy in anxiety, insomnia, and fibromyalgia maintains prescription volume.
• Cost competitiveness: Low-cost generics are preferred in emerging markets and for insurance coverage.
• Healthcare policies: There is a preference for non-paid or low-cost antidepressants within public health systems.

What are the primary challenges and risks?

• Shifts toward newer pharmaceuticals: SSRIs and SNRIs offer improved side-effect profiles, reducing reliance on tricyclics.
• Side effect profile: Anticholinergic effects and overdose risks restrict use in certain populations.
• Regulatory changes: Stricter guidelines for off-label use and safety warnings affect prescribing patterns.
• Market saturation: High generic penetration limits price growth.

How does market demand forecast through 2030?

Year	Market Size (USD billion)	CAGR	Notes
2022	1.1	—	Base year
2025	1.2	2.1%	Slight growth from increased off-label use and chronic pain management
2030	1.3	2.1%	Market stabilizes with slow growth as newer options penetrate the market

What are the future financial prospects?

The overall market remains stable, with generating revenue primarily from mature markets like North America and Europe, where generic penetration is high. Emerging markets show growth potential due to expanding healthcare infrastructure and affordability.

Generic manufacturing costs average USD 0.02-0.05 per unit, enabling profit margins upward of 40-50% depending on sales volume. Price compression persists, but volume sales compensate for margins.

What is the impact of strategic moves like patent extensions or new formulations?

• Patent extensions are not applicable post-1989; no recent patent litigation exists.
• Reformulations or combination therapies remain uncommercialized for amitriptyline hydrochloride, limiting new revenue streams.
• Companies are focusing on expanding indications for existing formulations rather than developing new proprietary versions.

Key Takeaways

• Amitriptyline hydrochloride’s market is mature with stable demand driven by chronic pain and off-label uses.
• Generic competitors dominate, maintaining low prices and high volume sales.
• Market growth remains slow at 2.1% CAGR to 2030, constrained by newer antidepressants and safety concerns.
• Emerging markets provide growth opportunities owing to healthcare infrastructure expansion.
• Cost structures favor high margins for manufacturers, but price pressure limits revenue upside.

FAQs

1. Will patent protections return for amitriptyline hydrochloride?

No. The original patent expired in 1989. No new patents are pending or in process for formulations.

2. What alternative drugs are replacing amitriptyline in depression treatment?

Selective serotonin reuptake inhibitors (SSRIs) such as sertraline and fluoxetine have largely replaced tricyclics due to better safety profiles.

3. Are there any ongoing clinical trials for new uses of amitriptyline?

Current research explores off-label applications such as OCD and post-traumatic stress disorder, but no significant new indication approvals are imminent.

4. How do safety concerns influence prescribing patterns?

Risks of overdose and anticholinergic side effects lead clinicians to favor newer agents, particularly in populations with higher risk of adverse effects.

5. What are the major regulatory regions influencing sales?

North America and Europe account for approximately 70% of sales, with India and China representing growth markets due to lower manufacturing costs and increasing healthcare access.

---

References

[1] Grand View Research. (2023). Amitriptyline Market Size, Share & Trends Analysis Report, 2023-2030.
[2] U.S. Food and Drug Administration. (2022). Generic Drug Approvals.
[3] IQVIA. (2022). Global Trends in Antidepressant Usage.